Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy

Clinical and Experimental Immunology

Volumn 114, Issue 3, 1998, Pages 347-354

  Logan, T F ^a   Banner, B ^a,c   Rao, U ^a   Ernstoff, M S ^a,d   Wolmark, N ^a   Whiteside, T L ^a   Miketic, L ^b   Kirkwood, J M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Autologous tumour vaccine; IL 2; Immunotherapy; In vitro; Renal cell cancer; Sensitization; T cell adoptive

Indexed keywords

BCG VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BCG VACCINATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CASE REPORT; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VON HIPPEL LINDAU DISEASE;

ADULT; CANCER VACCINES; CARCINOMA, RENAL CELL; ENDOTHELIUM; FEMALE; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; KIDNEY NEOPLASMS; LUNG NEOPLASMS; T-LYMPHOCYTES;

EID: 0031737289     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00731.x     Document Type: Article

References (36)

1. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic melanoma. N Engl J Med 1985; 313:1485-92.
2. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-97.
3. Fisher RI, Coltman CA Jr, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern, Med 1988; 108:518-23.
4. Sosman JA, Kohler PC, Hank JA et al. Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988; 80:1451-61.
5. Parkinson DR, Fisher RI, Rayner AA et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 1990; 8:1630-6.
6. Ernstoff MS, Nair S, Bahnson RB et al. A phase la trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 1990; 8:1637-49.
7. Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6:839-53.
8. Tykka H. Active specific immunotherapy with supportive measures in the treatment of advanced palliatively nephrectomised renal adenocarcinoma. A controlled clinical study. Scan J Urol 1981; 63 (Suppl.):1-110.
9. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990; 32:62-66.
10. Sahasrabudhe DM. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod 1986; 5:581-94.
11. Logan T, Kirkwood J, Wolmark N et al. Pilot study of in vitro sensitized (IVS) T cells in adoptive transfer therapy of cancer. ASCO 1990; 9 (Abstr.):188.
12. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 1989; 143:740-8.
13. Shu S, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985; 45:1657-62.
14. Shu S, Rosenberg SA. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol 1985; 135:2895-903.
15. Shu S, Chou T, Rosenberg SA. In vitro, sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol 1986; 136:3891-8.
16. Shu S, Chou T, Rosenberg SA. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Res 1987; 47:1354-60.
17. Shu S, Chou T, Rosenberg SA. Generation from tumor-hearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 1987; 139:295-304.
18. Chou T, Chang AE, Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. J Immunol 1988; 140:2453-61.
19. Chou T, Bertera S, Chang AE, Shu S. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 1988; 141:1775-81.
20. Logan TF, Shu S, Bahnson RR, Leong SPL, Banner BB. Generation of specific cytolytic cells from patients with melanoma (ME) and renal cell carcinoma (RCC) by in vitro sensitization (IVS). AACR 1989; 30 (Abstr.):342.
21. Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother 1988; 26:1-10.
22. Whiteside TL, Bryant J, Day R, Herherman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 1990; 4:102-14.
23. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63.
24. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989; 49:7086-92.
25. Maher ER, Yates JRW, Harries R et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 283:1151-63.
26. Lamiell JM, Salazar FG, Hsia YE, Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989; 68:1-29.
27. Connor JM, Von Hippel-Lindau Disease. Q J Med 1990; 77:1099-100.
28. Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 1990; 46:1001-6.
29. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-67.
30. Logan T, Elder E, Whiteside T et al. In vitro sensitized T cells given in a phase II study demonstrate differential proliferation and cytokine release to autologous tumor. J Immunother 1995; 18 (Abstr.):133.
31. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 1993; 53:1043-50.
32. + tumor infiltrating lymphocytes. J Exp Med 1991; 173:647-58.
33. Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 1993; 53:4745-9.
34. Hashimura T, Tubs RR, Connelly R et al. Characterization of two cell lines with distinct phenotypes and genotypes established from a patient with renal cell carcinoma. Cancer Res 1989; 49:7064-71.
35. Sarna G, Figlin R, de Kernion J. Interferon in renal cell carcinoma. The UCLA experience. Cancer 1987; 59:610-2.
36. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol 1977; 117:272-5.